Published Article: Evolution of Antisense Oligonucleotides in Oncology Published Article Evolution of Antisense in Oncology
Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development
Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma BPTH_NHL_data_AACR
Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference BPTH_Oppenheimer_Webcast
